Pharma News, 2024

Clinical trials demonstrated felzartamab’s potential to improve outcomes in diseases caused by pathogenic antibodies. Felzartamab is being developed to treat antibody-mediated rejection in kidney tr...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory disease...

Researchers from the Cancer Research UK (CRUK) Scotland Institute and the University of Glasgow have revealed that imaging technology could be used as a new approach for diagnosing and treatin...

Despite being a key revenue generator for Merck (MSD), recent months have seen Keytruda (pembrolizumab) navigating a rocky terrain in the non-small cell lung cancer (NSCLC) spa...

Bristol Myers Squibb (BMS) has announced that Abecma (idecabtagene vicleucel) has been approved by the European Commission (EC) to treat patients with relapsed or refractory mu...

The one-time treatment, Lenmeldy, is used to correct the underlying cause of a hereditary condition called early-onset metachromatic leukodystrophy.

AdCom voted eight to three in favour of BMS and 2seventy bio’s CAR-T cell therapy, Abecma, in triple-class exposed multiple myeloma patients. Abecma is a B-cell maturation antigen (BCMA) dir...

BMS has acquired Karuna's lead asset, KarXT (xanomeline-trospium), along with its early-stage and pre-clinical pipeline.

Novartis has broken ground on the expansion of its biopharmaceutical manufacturing facility in Singapore, which aims to meet the increasing demand in the Asian market.

The decision makes available in the U.S. a gene therapy GSK first began working on more than a decade ago.

As AstraZeneca looks to move past chemotherapy and radiotherapy, it will enter a market firmly controlled by Novartis.  

The US Food and Drug Administration (FDA) has approved BeiGene’s TEVIMBRA (tislelizumab-jsgr) for the treatment of adults with unresectable or metastatic oesophageal squamous cell ca...